Zogenix Inc., of San Diego, filed a registration statement to raise funding through the public offering of 12 million shares – 13.8 million if underwriters exercise their full overallotment option. Based on Monday's closing price of $3.40 per share, the company anticipates net proceeds of about $37.7 million – or $43.5 million with overallotments – to support submission of a new drug application for Zohydro, other clinical and commercialization activities and for general corporate purposes.